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This NATA position statement was developed by the NATA Research & Education Foundation.
Objective: This manuscript summarizes the best available
scholarly evidence related to anabolic-androgenic steroids
(AAS) as a reference for health care professionals, including
athletic trainers, educators, and interested others.
Background: Health care professionals associated with
sports or exercise should understand and be prepared to
educate others about AAS. These synthetic, testosteronebased derivatives are widely abused by athletes and nonathletes to gain athletic performance advantages, develop their
physiques, and improve their body image. Although AAS can

be ergogenic, their abuse may lead to numerous negative
health effects.
Recommendations: Abusers of AAS often rely on questionable information sources. Sports medicine professionals can
therefore serve an important role by providing accurate, reliable
information. The recommendations provide health care professionals with a current and accurate synopsis of the AAS-related
research.
Key Words: testosterone, androgen, ergogenic aids, drugs,
abuse, doping, sport, athletes

__________________________________________________________________________________________________

A

nabolic-androgenic steroids (AAS) are synthetic
testosterone analogs1,2 legally classiﬁed as Schedule III controlled substances.1,3 These hormones
increase lean muscle mass and can improve athletic
performance.1,2,4,5 Although AAS have valid medicinal
uses, nontherapeutic abuse also occurs.1,4,5 Recent increases
in androgen prescriptions are evident.6,7 Those involved in
organized athletics and nonathletes both abuse AAS.1,2
Nontherapeutic users often obtain AAS information and
products from a variety of dubious sources and make
questionable health decisions.8,9 Health care professionals,
including athletic trainers and educators, may interact with
individuals who abuse or intend to abuse AAS. Therefore, it
is imperative that such professionals understand these
substances so that they can educate others using the most
current and accurate evidence.
This position statement is a summation of the best
available scholarly evidence with regard to AAS and
integrates a Strength of Recommendation Taxonomy
(SORT) criterion scale from the American Academy of

Family Physicians (Table 1).10 Recommendations are
ranked as A (good-quality evidence), B (inconsistent or
limited-quality or limited-quantity evidence), or C (recommendations based on consensus, usual practice, opinion, or
case series). Although other frequently abused pharmaceuticals (eg, human growth hormone, insulin growth factor 1,
and selective androgen receptor modulators) and nutritionals (eg, creatine, amino acids, protein powders) purport
to promote anabolism, this position statement solely
addresses AAS. For logistical and ethical reasons, few
prospective, outcome-based, scholarly studies duplicated
the typical nontherapeutic AAS abuse patterns often
used.11–13
Health care professionals owe their patients evidencebased knowledge to help in their health care decisions.
Identiﬁcation of the AAS abuser (or potential abuser) by a
health care professional is critical to help prevent any
negative consequences. Proper direction, guidance, support,
and possible referral are essential in assisting AAS abusers
and potential abusers.
Journal of Athletic Training
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Table 1. Strength of Recommendations Taxonomy (SORT)a,10
Strength of
Recommendation
A

Recommendation based upon consistent and good-quality patient-oriented evidence (morbidity, mortality, symptom
improvement, cost reduction, and quality of life)b
Recommendation based on inconsistent or limited-quality patient-oriented evidenceb
Recommendation based on consensus, usual practice, opinion, disease-oriented evidence (measures of intermediate,
physiologic, or surrogate end points that may or may not reflect improvements in patient outcomes), or case series
for studies of diagnosis, treatment, prevention, or screening

B
C

a

b

Definition

Reprinted with permission from ‘‘Strength of Recommendation Taxonomy (SORT): A Patient-Centered Approach to Grading Evidence in
the Medical Literature,’’ February 1, 2004, Vol 69, No 3, American Family Physician. CopyrightÓ 2004 American Academy of Family
Physicians. All Rights Reserved.
Patient-oriented evidence measures outcomes that matter to patients: morbidity, mortality, symptom improvement, cost reduction, quality
of life. Disease-oriented evidence measures intermediate, physiologic, or surrogate endpoints that may or may not reflect improvements in
patient outcomes (ie, blood pressure, blood chemistry, physiological function, and pathological findings).

RECOMMENDATIONS

Therapeutic AAS Use and Nontherapeutic AAS Abuse

Basic Science

5. Health care professionals and educators should recognize
the possible therapeutic uses for AAS, which include
therapy for male hypogonadism, certain rare anemias, and
other medical conditions; anticatabolism for those with
chronic wasting syndromes; and preserving or restoring
bone health.6,7,18–20,24–33 Although some suggest AAS may
act as ‘‘antiaging’’ substances, the evidence remains
questionable.6,17,18,33 Evidence Category: C
6. Health care professionals and educators should appreciate
that although AAS prevalence studies have limitations, the
current evidence suggests that nontherapeutic AAS use is a
worldwide phenomenon.3,8,9,34–49 Abuse of AAS occurs for
performance improvement, physique development, and
body-image enhancement.8,9,34–44,46,49 Males abuse AAS at
greater frequency than do females.8,35,36,45,46 Those who
use AAS for nontherapeutic reasons often do not
participate in organized sports.9,41,43,45,46,49 Abusers of
AAS include adolescents, collegians, professional and
Olympic athletes, body builders, and recreational athletes,
among others.8,34–37,39–47,49 The nonmedicinal abuse of
AAS often begins in adolescence, sometimes as early as
middle school.35–37,41–43,45–47 Evidence Category: C
7. Health care professionals and educators should realize that
AAS abusers choose from many possible agents,11,50
including ‘‘designer steroids’’ unapproved by the Food and
Drug Administration and veterinary-quality and blackmarket substances.1,3,13,41,49 Although AAS abusers may
obtain androgens from physicians, their supplies more
commonly come from other sources, such as the Internet,
training partners, gymnasium owners or instructors, teammates, and coaches.8,9,36,37,40–42,49 Counterfeit AAS are
common, lending to product quality concerns: impurities,
contaminants, and inaccurate product labels.51–53 Evidence
Category: C
8. Health care professionals and educators should understand
that doses taken by AAS abusers are often much greater
than therapeutic replacement levels.13,14,51,53,54 Nontherapeutic AAS users frequently ‘‘stack,’’ or simultaneously
abuse, multiple AAS, with differences in half lives and
solubilities.3,9,36,41,44,45 Abuse of AAS often occurs in
repeated cycles of 6 to 12 weeks, followed by periods of
nonuse.1,3,8,9,36,41 Evidence Category: B

1. Health care professionals and educators should recall that
the endocrine system synthesizes hormones that help
regulate the body’s physiology. Primarily synthesized in
the gonads and adrenal glands, steroid hormones are a
particular class of chemical messengers that affect body
tissues and have anti-inﬂammatory, salt-retaining, and
feminizing or masculinizing properties, depending on the
substance.1,4,7,14–16 Evidence Category: A
2. Health care professionals and educators should understand
that testosterone, the key androgen, promotes both
androgenic (masculinizing) and anabolic (tissue-building)
effects.1,4,7,14–16 Normal testosterone levels vary with age,
sex, and health status, and levels in males are signiﬁcantly
greater than levels in females.7,17–19 In males, testosterone
levels normally peak during early adulthood and then
decrease.7,18–20 Abnormal endogenous testosterone levels
in adulthood appear to be associated with speciﬁc disorders
or diseases.7,18–20 Evidence Category: A
3. Health care professionals and educators should appreciate
that AAS are synthetic substances related to the primary
male hormone, testosterone.1,2,4,7,14 The United States
classiﬁes the many available AAS as Schedule III
controlled substances.1,13–15 Pharmaceutical companies
and clandestine laboratories may develop various AAS to
maximize anabolic effects, minimize androgenic effects,
improve pharmacokinetics, increase receptor afﬁnity, and,
in some cases, avoid detection.14,15 The AAS are available
as oral, injectable, and buccal (intraoral, next to cheek)
agents, subcutaneous pellets, and transdermal patches,
creams, and gels.14,15 Evidence Category: A
4. Health care professionals and educators should know that
the mechanisms of action for AAS are complex and
variable.7,14,15 The AAS appear to promote protein
synthesis through increased transcription while also acting
as glucocorticoid antagonists, limiting catabolism.14,15
They also induce various potentially ergogenic psychotropic actions, altering neurochemistry,11,14,21,22 and may
stimulate human growth hormone and insulin growth
factor 1 synthesis,12 as well as downregulate myostatin.7,23,24 Evidence Category: C
568
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AAS Efficacy
9. Health care professionals and educators should respect the
limitations of high-quality research designs in determining AAS effectiveness and side effects.11–14,22,51,55,56
Ethical issues disallow using the typically extreme dosing
schedules in research studies due to the federally
controlled status of AAS, as well as the reported risk
proﬁle of androgen use at nontherapeutic doses.11,14,51,55,56
Evidence Category: C
10. Health care professionals and educators should realize that
the efﬁcacy of AAS as anabolic agents suggests a doserelated potential for increased relative lean body mass.57–61
These substances can generally act as ergogenic agents
when the measure involves strength- or power-related
performances.6,59–66 Evidence Category: A
AAS Abuse Health Effects

Health care professionals and educators should be aware
of the following possible AAS abuse side effects on various
biologic systems and organs.
11. Supraphysiologic AAS dosing may occasionally be
associated with hypomanic or manic syndromes that are
often characterized by irritable or aggressive behavior.21,54,67–78 Episodes of major depression may be
associated with AAS withdrawal.79–81 Abusers of AAS
may develop a dependence syndrome related to both
myoactive and psychoactive effects82–89 and may exhibit
other forms of drug dependence, such as opioids.83,90–93
Evidence Category: B
12. The cardiovascular effects of therapeutic AAS remain
unclear. Substantial research ﬁndings now suggest that
AAS abuse negatively inﬂuences the cardiovascular
system.25,67,94–103 The best evidence indicates that nontherapeutic AAS-related conditions include cardiomyopathy 96,97,99,100 and the potential for atherosclerotic
vascular disease caused by detrimental lipid changes,
which may adversely affect one’s risk for coronary artery
disease.25,102,103 Evidence Category: B
13. Although rare, hepatic maladies including cholestatic
jaundice and peliosis hepatis might occur with the
nontherapeutic abuse of AAS, especially when the oral
C17a-alkylated group of AAS is involved.7,11–14,22,24,51,55,104
Evidence Category: A
14. Exogenous AAS abuse inhibits the hypothalamic-pituitary-gonadal axis, reducing the production of endogenous
testosterone, luteinizing hormone, and follicle-stimulating
hormone.7,11–14,22,51 It can also alter thyroid function11,12,22
and negatively affect glucose tolerance.12,22,105 Evidence
Category: B
15. Abuse of AAS directly affects the male reproductive
system, with possible side effects including hypogonadism,
decreased spermatogenesis, decreased sperm motility,
erectile dysfunction, impotence, gynecomastia, and malepattern baldness.7,11–14,22,51,55 Many of these conditions are
reversible with cessation of AAS, although breast tissue
changes and hair loss often require additional treatments,
including surgery.7,11–13,22,51,55 Evidence Category: B
16. Reproductive changes to females who abuse AAS
generally involve virilization, including voice deepening,
hirsutism, clitoral hypertrophy, breast reduction, libido

changes, menstrual dysfunction, male-pattern baldness,
and acne.11–14,22,51 Unlike the side effects in males, many
of these changes are permanent in females.12,14,22
Evidence Category: B
17. Skeletally immature AAS abusers might experience
premature epiphyseal closure of the long bones, resulting
in shortened stature.11,12,14,22,51 Other negative effects of
AAS abuse on the musculoskeletal system may include
tendinopathies (including possible rupture).7,11–13,22,51
Little evidence supports the therapeutic use of AAS for
musculotendinous injury recovery.7,106 Evidence Category: C
18. A possible immunosuppressant effect of AAS abuse may
exist in humans.11,22,107 Abusers risk local and systemic
infections (including hepatitis and human immunodeﬁciency virus) with unsterile syringe usage.11,12,14,22
Evidence Category: B
19. High-dose AAS abuse often leads to a number of
dermatologic conditions, most commonly some form of
acne.11,12,14,22,108,109 Kidney structure and function may be
at risk with supraphysiologic doses of AAS, especially
when combined with use of nonsteroidal anti-inﬂammatory
drugs, high-protein diets, certain nutritional supplements,
and dehydration.11,22,51,55,110,111 Gingival and other oral
tissues may also be affected.52,112 Evidence Category: C
AAS Abuse Prevention
20. Health care professionals and educators should recognize
the great variance in drug testing programs.113 Due to the
small number of high-quality studies, whether such
screenings signiﬁcantly deter AAS abuse remains unclear.114,115 A need exists for prospective randomized
trials to investigate the deterrent efﬁcacy of AAS
screening. Evidence Category: C
21. Health care professionals and educators should realize
that although AAS abuse education requires further
study, well-designed programs might effectively inhibit
such abuse in adolescents.114–124 Consideration for the
early integration of prevention models into educational
curricula and sports programs is important. Evidence
Category: C
AAS Abuse Identification and Intervention
22. Health care professionals and educators should be aware
of the dynamic, social process of AAS abuse. Active
monitoring for AAS abuse and maintaining an open,
honest, and evidence-based dialogue with all stakeholders, including athletes, coaches, administrators, parents,
advisory groups, and others, is vital.125,126 Athletic
trainers should develop relationships with and call on
other qualiﬁed health care professionals as referral
resources. Evidence Category: C
BACKGROUND AND LITERATURE REVIEW
History of Anabolic-Androgenic Steroids

Testosterone Isolation and Development. More than
6000 years ago, herders recognized numerous changes in
castrated animals. 1,16 Centuries later, crude studies
Journal of Athletic Training
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investigating the testes’ biologic role involved their transfer
from castrated roosters into the abdominal cavity of hens to
observe changes in the animals.1,16 In the mid-1800s, the
effects of castration were directly related to a secreted
testicular substance.1,16 Charles Brown-Séquard, a founder
of endocrinology, published results suggesting remarkable
rejuvenation effects from his self-experimentation using
guinea pig and canine testicular extract.1,2,16 Testosterone
was eventually chemically isolated 1,2 ,5 and then
synthetically developed. 1,2,16 In 1935, Kockakian
suggested testosterone might help stimulate anabolism
and beneﬁt certain wasting conditions.2 Thereafter, sports
physiology researchers began investigating the effects of
testicular extracts on physical performance.1,2,5
AAS Ergogenics. The 1940s brought the ﬁrst published
reports on the ergogenic effects of testosterone and its
derivatives.2 The 1945 book The Male Hormone may have
increased athletic AAS abuse.1,2,7 Anecdotal reports
described West Coast body builders experimenting with
AAS in the late 1940s.1,2,16 The 1952 Helsinki Olympic
Games brought about the seemingly valid US claim of
hormonal manipulation by the successful Soviet
weightlifters.4,5 Soviet physicians purportedly admitted that
their athletes used synthetic hormones at the 1954 World
Weightlifting Championships.5 This led to the development
and 1958 release of the ﬁrst commercially available AAS in
the United States: methandrostenolone (Dianabol; Ciba
Specialty Chemicals, Basel, Switzerland).1,4,5,7
Abuse of AAS increased through the 1960s and 1970s,4,5
with evidence for abuse at every Olympic competition since
1960.4 The abuse spread to professional and collegiate
sports,5 and typical dosages increased well beyond
therapeutic levels.14 This era also involved large-scale,
top-secret, government-supported, systemic hormonal manipulation in some Eastern bloc countries.4 Increased AAS
abuse led to the 1967 establishment of the International
Olympic Committee’s Medical Commission, with the
primary role of doping oversight.4 Urine AAS tests were
ﬁrst conducted at the 1974 Commonwealth Games, where
more than 16% of the sampled athletes tested positive.5 The
1976 Montreal Games marked the ﬁrst Olympic AAS
tests.4,5 During this time, most other sport governing
bodies, including colleges and professional leagues,
generally did little to address AAS abuse.5
Although AAS abusers learned about the efﬁcacy of these
substances through trial and error, many medical professionals and scientists erroneously suggested that these drugs
were ineffective based on laboratory studies that failed to
duplicate the doses and training conditions experienced by
actual AAS abusers in the ﬁeld.4,5,14,51 This discrepancy led
to distrust of the science and those reporting it.5,51 Drug
testing and the knowledge gap pushed AAS abuse further
underground.4,5 Many trade publications promoting AAS
abuse became available in the 1970s and 1980s.4,5 Ben
Johnson’s apparent gold medal and world record at the
1988 Seoul Olympics highlighted the enormity of AAS
abuse.4 The 1990 Anabolic Steroid Control Act reclassiﬁed
many AAS as Schedule III controlled substances.1 A
follow-up statute—the Anabolic Steroid Act of 1994—
added more AAS and some testosterone precursors to the
Schedule III drug list.1
So-called designer steroids became known4 when a
contaminated needle was anonymously sent to the US
570
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Anti-Doping Agency in 2003. The substance was a new
AAS not approved by the US Food and Drug Administration and since named tetrahydrogestrinone.4 These ﬁndings
led to the Bay Area Laboratory Cooperative (BALCO)
scandal that involved many high-proﬁle athletes.4,127 The
US Congress held hearings concerning AAS abuse, leading
to the 2004 Anabolic Steroid Control Act, which reclassiﬁed many anabolic-related pharmaceuticals as Schedule III
controlled substances.53,107
In 2004, the World Anti-Doping Agency began AAS
oversight for all international competitions involving
Olympic sports.4 Many collegiate sport organizations, as
well as US professional sport leagues, now include AAS
testing, although the rigor of these programs varies
greatly.113 Some modern competitors continue to seek
increasingly sophisticated, illegal, and unethical ways to
maximize their performance or physique (or both) with
AAS.4 The most common source of positive doping tests by
the World Anti-Doping Agency is AAS.4,51
Epidemiology of AAS Abuse

Although AAS have legal therapeutic uses for speciﬁc
medical disorders, healthy persons also abuse them to
enhance physical performance or physique (or
both).1,2,4,5,7,14 Researchers have most frequently concentrated on the prevalence of AAS abuse but have also
investigated commonly abused AAS, abuser characteristics,
patterns of abuse, and AAS sources.3,8,9,35–46 These abuser
proﬁles are important to understand before educational and
preventive initiatives are devised.
Prevalence of Nontherapeutic AAS Abuse. Most
authors of prevalence studies used anonymous, direct
survey methods, typically within speciﬁc populations, such
as adolescents, collegians, elite athletes, or gym attendees.
Many published reports with various research designs
detailed AAS prevalence rates (Table 2).3,8,9,34–47,49,128
Anonymous survey research, although valuable, involves
limitations, and interpreting results requires caution. For
example, respondents may falsely indicate they used
steroids when they actually used only corticosteroids or
dietary supplements.129 Alternatively, those who complete
such questionnaires may be less likely to abuse drugs. Given
these possibilities, the research results presented here
generally include those studies with the strongest sampling
techniques, sample sizes, survey administrations, and
reporting methods, as well as documentation of instrument
validity and reliability.3,8,9,34–47
Adolescent AAS Abuse. Adolescents are the most
studied population for the prevalence of AAS abuse
(Table 2). The ﬁrst national high school survey (1988)
suggested AAS abuse by 6.6% of male high school
seniors.41 A survey of male Indiana high school athletes
in 1999 indicated a 6.3% lifetime prevalence of AAS
abuse.42 In 2002, others34 suggested that 0.7% of sport
participants aged 10 to 15 years from 34 states abused
AAS. A 2006 US study of junior high and high school
students reﬂected an AAS abuse prevalence of 1.3%,
including 2.7% of males and 0.4% of females.46 Results
from a 2007 study of Minnesota students in grades 7
through 12 indicated AAS abuse rates of 1.7% and 1.4% in
male and female adolescents, respectively.43 The 2009
Centers for Disease Control and Prevention Youth Risk
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Author(s) (Year)

772

772
511
260
123

Kanayama et al (2001)48

Perry et al (2005)9

Santos et al (2010)49

123

NA

334

136

15

108

146

15

176

2552

NA

NA

833

Baker and Graham
(2006)45
Bolding et al (2002)44

Wagman et al (1995)40

Tricker et al (1989)38

20 474

National Collegiate Athletic
Association (2012)37
Horn et al (2009)39
2552

54 567

McCabe et al (2007)3

1185

NA

Group Description

United States
(12 states)
Europe (6
countries)
Indiana

Europe (35
countries)

United States

United States

Location

Students at high
schools
Football athletes at
347 high schools
Students at 31 junior Grades
St Paul, MN
high and high
7–12
schools
Athletes in youth
Range, 10– United States
sports
15 years
(34 states)
Students at high
Grades
United States
schools
9–12

Grades
8–12
Average,
16 y
NA

Average,
15.8 y

Grades
7–12

Grade 12

Age/
Grade

0

NA

177

0

10

Retired National
Football League
players
National Physique
Committee
registered
bodybuilders
Elite powerlifters

Average,
26.7 y

Average,
53.8 y

Range,
20–45 y
Convenience
Clients at ‘‘hardcore’’ Average,
gyms
33.6 y
Convenience
Gay male attendees Median,
at 6 gyms
35 y
Convenience
Clients at 5 gyms
Range,
14–70 y
Self-selected via Weight lifters and
NA
Internet
bodybuilders
Convenience
Bodybuilders
Range, 18–
50 years

0 Population

68 Population

0 Population

Brazil

United States

Boston, MA

South Wales,
UK
London, UK

United States

Kansas and
Missouri

United States

352 Stratified random Athletes at ten 2-year Average,
California
cluster
colleges
19.6 y
NA Random cluster Students at 119 4About 21 y United States
year colleges
NA NA
Collegiate athletes
NA
United States

NA 2-Stage cluster
sample

474 Cluster

1386 Selected

0 Random cluster

NA Cluster

0 Stratified random Students at 46 high
cluster
schools
7563 Representative
Students at junior
sample
high and high
schools
53 579 Populations or
Students (1991
births)
representative
clusters
1689 NA
Students

Sampling
Technique

41

207

18

117

102

10

66

233

NA

NA

38

NA

11*

38*

55

388

NA

NA

183

226

33.3

79.6

3.5

15.2

69.9

66.7

37.5

9.1

0.8

1.0

3.3

3.3

0.7

1.5*

6.3

2.1

1.6

NA

1.3*

6.6

41

NA

18

117

NA

10

59

233

NA

NA

34

NA

10*

19

55

NA

NA

NA

153

226

33.3

NA

5.4

15.2

NA

66.7

54.6

9.1

NA

NA

4.2

4.3

0.9

1.7

6.3

NA

2.4

2.0

2.7

6.6

0

NA

0

0

NA

NA

7

0

NA

NA

4

NA

1*

19

0

NA

NA

NA

30

0

0.0

NA

0.0

0.0

NA

NA

10.3

0.0

NA

NA

1.2

2.2

0.2

1.4

0.0

NA

0.8

1.0

0.4

0.0

Total
Total
Male
Male Female Female
Abusers Abusers Abusers Abusers Abusers Abusers
(n)
(%)
(n)
(%)
(n)
(%)

Abbreviations: AAS, anabolic-androgenic steroids; *, numbers were calculated by present authors, not directly stated by original authors; NA, not available.

Gym
attendees

Elite
athletes

Collegians

16 410

1553

Wroble et al (2002)34

Centers for Disease
Control and Prevention
(2009)35
Kersey (1996)8

1130

2516

1079

873

873

NA

1559

3248
18 430

51249

6759

3403

104 828

14 322

3403

Stilger and Yesalis
(1999)42
vandenBerg et al (2007)43

Kokkevi et al (2008)36

European School Survey
Project on Alcohol and
Other Drugs (2007)47
Hoffman et al (2007)53

Dodge and Jaccard
(2006)46

Adolescents Buckley et al (1988)

AAS Abusers

Total
Participants, Males, Females,
N
n
n

Table 2. Anabolic-Androgenic Steroid Abuse Prevalence Studies Implementing the Highest-Quality Research Techniques

Table 3. Available Anabolic-Androgenic Steroids, Including Veterinary Pharmaceuticals
Generic Name

Trade Names

Formula

Administration

Testosterone
Gel
Patches
Pellets
Buccal system
Suspension
Testosterone propionate
Testosterone enanthate
Testosterone cypionate
Testosterone undecanoate
Nandrolone decanoate
Boldenone undecylenate
Methenolone enanthate
Oxandrolone
Methandrostenolone
Fluoxymesterone
Oxymetholone
Methyltestosterone
Trenbolone acetate
Stanozolol

AndroGel, Axiron, Testim, Fortigel
Testoderm, Androderm
Testopel
Striant
Testosus, Aquaviron, Univet Uni-test
Testrex, Androgeston, Testogen
Delatestryl, Primotestone, Testinon
Depo-Testosterone, Durandro
Andriol, Undestor, Nebido
Deca-Durabolin, Anabolin
Equipoise, Ganadol, Equigon
Primobolan depot, Delapromor
Anavar, Oxandrin, Vasorome
Dianabol, Anabol, Refovit
Halotestin, Fluotestin, Ora-Testryl
Anadrol, Roboral, Anasteron
Android, Testred, Methitest
Finaplix H, Finaplix S, Parabolan
Winstrol, Stromba, Winstrol V

C19H28O2
C19H28O2
C19H28O2
C19H28O2
C19H28O2
C22H32O3
C26H40O3
C27H40O3
C30H48O3
C28H44O3
C30H44O3
C27H42O3
C19H30O3
C20H28O2
C20H29FO3
C21H32O3
C20H30O2
C20H24O3
C21H32N2O

Transdermal
Transdermal
Subcutaneous
Buccal
Injection
Injection
Injection
Injection
Injection
Injection
Injection
Injection
Oral
Oral
Oral
Oral
Oral, buccal, sublingual
Oral, injection, pellets
Oral/injection

Behavior Surveillance System35 reported that national AAS
abuse rates were 4.3% and 2.2% for males and females,
respectively (3.3% overall). Results from the 2007
European School Survey Project on Alcohol and Other
Drugs involving 35 European nations noted an AAS abuse
prevalence of 2% for males and 1% for females.47 A 2008
six-country European study reﬂected an overall AAS abuse
prevalence of 2.1% among high school students.36
Collegiate AAS Abuse. The National Collegiate Athletic
Association (NCAA), among others, studied AAS abuse
among collegiate student-athletes every 4 years since 1985.
The most recent (2009) ﬁndings (Table 2) indicated an
overall lifetime AAS abuse prevalence of 0.8%.37 A
summation of 4 independent studies at 119 US
universities indicated that 0.9% of all college students
abused AAS.3 Only one author8 investigated AAS abuse
among community college student-athletes and reported a
prevalence of 3.3% (4.2% of men, 1.2% of women).
Elite Athlete AAS Abuse. The prevalence of AAS abuse
by elite athletes has been examined in relatively few highquality studies (Table 2).38–40 In a 1989 study,38 37.5% of
competitive body builders admitted AAS abuse, whereas a
1995 investigation revealed that 66.7% of competitive
power lifters abused AAS.40 A 2009 paper39 indicated that
9.1% of retired National Football League athletes admitted
using AAS during their professional careers. Prevalence
was highest among offensive (16.3%) and defensive
(14.8%) linemen.
Gym Attendee AAS Abuse. A few well-designed studies
described AAS abuse by gym attendees (Table 2). A 5.4%
reported lifetime prevalence of AAS abuse was
demonstrated among 334 men in 5 Boston-area gyms, but
no cases of AAS use among 177 women were noted.48 In a
high-quality British study,44 AAS abuse was found in
15.2% of gay male gym attendees. In body-building gyms,
AAS abuse prevalence rates were 33.3% in Brazil49 and
69.9% in the United Kingdom.45
Commonly Abused AAS. Options for AAS abusers are
many,13–15 including pharmaceutical-grade, veterinaryquality, and unapproved AAS. 1,4,14,49,127 Abuse of
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‘‘designer’’ AAS, such as tetrahydrogestrinone and others,
developed outside the normal US Food and Drug
Administration approval process and is a recent and
apparently growing phenomenon. 1,4,14,127 The most
common administration routes are oral and parenteral,
although topical and transdermal routes are also
options.1,4,14,127 Examples of commonly abused AAS are
shown in Table 3.8,9,38,45,49
Patterns of AAS Abuse. Unique patterns of AAS abuse
evolved through anecdotal evidence, as well as trial and
error. Research14,54,127 suggests that most AAS abusers
administer doses well beyond medicinal levels. These doses
vary depending on the desired outcomes, but weekly totals
in excess of 1000 mg are not uncommon127; typical
medicinal doses for hypogonadal males are 35 to 70 mg
per week.7 Additionally, AAS abusers frequently ‘‘stack’’
(simultaneously administer) multiple AAS.1,4,8,9,41,45 Abuse
often occurs in cycles, or periods of use followed by
nonuse, typically lasting 6 to 12 weeks.1,4,8,9,41 The efﬁcacy
of these abuse patterns is unconﬁrmed by research, but
extreme athletic performances and physiques may indicate
that practice is ahead of science.1,127
AAS Abuser Characteristics. Many AAS prevalence
studies also gathered related demographic information that
helped to deﬁne the AAS abuser.3,8,35–37,46 A 2009 national
Centers for Disease Control and Prevention study of
adolescents found that male teens (4.3%) were more
likely to abuse AAS than female teens (2.2%). 35
Hispanics, whites, and blacks were the most likely AAS
abusers.35 In another investigation,46 an association was
suggested between sport participation and AAS abuse,
especially with males. Other authors36 reported a similar
association between AAS abuse and physical exercise in
European adolescents. Some researchers46 found a strong
association between the use of legal performanceenhancing substances and AAS, whereas others 36
suggested a similar association for recent alcohol abuse
and lifetime abuse of sedatives or cannabis.
The most recent NCAA study indicated collegians
typically begin their AAS abuse under age 20, with some

Figure 1. Chemical structure of steroid hormones with three 6carbon rings and one 5-carbon ring.

declaring their ﬁrst-time abuse occurring between ages 12
and 13.37 Most collegians claimed to abuse AAS to improve
athletic performance and for reasons unrelated to sports,
with fewer using AAS to treat injury.37 Males were more
likely than females to utilize nontherapeutic AAS within
the past 12 months.37 Other ﬁndings3 suggested that
collegiate AAS abusers tended to be married, male,
student-athletes, and older than 23 years of age. Although
students at commuter colleges had a higher prevalence of
AAS abuse, geographic region, NCAA division, institutional status (private versus public), and size were not
associated with the nontherapeutic use of AAS.3 These
authors reported a signiﬁcant association between AAS
abuse and cigarette smoking, binge drinking, illicit drug
abuse (marijuana and cocaine), and other risky behaviors.3
Sources of Nontherapeutic AAS. The United States
classiﬁes AAS as Schedule III controlled substances, which
require a prescription.1,3 Research indicates that AAS
abusers obtain their drugs through many venues.8,37,40,41,49
Among male high school senior AAS abusers, 60.5%
obtained their drugs via black-market sources, with about
20% obtained from physicians, pharmacists, and
veterinarians.41 Similarly, 59% of community college
abusers obtained their AAS through black-market
sources. 8 Physicians who provided AAS with a
prescription (26.5%) and without a prescription (8.8%)
were the next most common sources.8 Only 10% of AASabusing power lifters obtained their drugs from physicians
or pharmacists.40 The 2009 NCAA study revealed the most
common AAS source for collegiate abusers was a
teammate, friend, or family member. 37 About 14%
acquired their drugs via the Internet, whereas physicians,
coaches, and athletic trainers were the declared sources for
13%, 7%, and 6%, respectively.37 With many of these drugs
coming from nonmedicinal sources, one must always
consider the likelihood of contamination, as well as the
accuracy of the actual drug amount.52,127
AAS Pharmacology

Hormones are compounds produced by the endocrine
system that chemically regulate speciﬁc body functions.
Steroid hormones have a biochemically unique 4-ring
structure, including three 6-carbon rings and one 5-carbon
ring (Figure 1). 14 Androgens are steroid hormones

synthesized primarily in the gonads and adrenal
glands.1,4,7,14–16,51,127 Dihydrotestosterone, dehydroepiandrosterone, androstenedione, androstenediol, and testosterone are the human androgens (Figure 2).15 Testosterone
(Figure 3) is the key androgen promoting masculine
(androgenic) characteristics, as well as maintaining
nitrogen balance and facilitating protein synthesis (anabolism).14 Males synthesize 2.5 to 11 mg of testosterone per
day, whereas females produce about 0.25 mg daily.7
Although both males and females synthesize testosterone,
serum concentrations in males (300 to 1000 ng/dL) are
signiﬁcantly greater than in females (15 to 65 ng/dL).7 In
addition to individual differences and sex variability,
testosterone levels generally decline in older men and vary
with certain disease states (eg, adrenal gland disorders in
males and females, as well as polycystic ovary syndrome
and rare ovarian cancers in women).7,17–20
Throughout history, pharmaceutical companies and
clandestine laboratories developed scores of unique derivatives of the endogenous androgenic hormones, including
testosterone (Table 3).13–15 New AAS innovations seek to
enhance or minimize certain effects, improve administration or absorption, improve receptor afﬁnity, and, more
recently, avoid detection.14,15 Frequently, efforts are
focused on facilitating anabolism and inhibiting androgenesis, although to date no AAS are solely anabolic.7,14
Pharmacokinetics. Unaltered oral testosterone is readily
metabolized by the liver, so pharmaceutical companies
modify the molecule or the delivery system to enhance its
bioavailability, change its rate of absorption, and enhance
or diminish its various characteristics.14 Traditionally, AAS
administration routes included oral or parenteral routes and
subcutaneous pellets, but buccal and transdermal methods
are now also available.14,15 Testosterone and its derivatives
are often alkylated at the 17b-hydroxy position to decrease
ﬁrst-pass liver metabolism when administered orally.14,15
Esteriﬁcation at the 17b-hydroxy site makes AAS
molecules less polar and more soluble as an oil-based
injectable.14,15
Once absorbed into the blood, AAS pass throughout the
circulatory system, generally bound to either sex-hormonebinding globulin or more loosely to the plasma protein
albumin.7,14,15 Less than 2% of testosterone remains
unbound and freely available.7,9 Commonly metabolized
by the liver, AAS molecules convert to androsterone and
etiocholanolone.7,15 These biologically inert compounds
undergo glucuronidation or sulfation and are primarily
excreted through the urinary system.14
Pharmacodynamics. The AAS are exogenous synthetic
derivatives of, and generally function as agonists for, the
androgen hormones.1,2,4,7,14 The AAS mechanism of action
occurs at the cellular level and requires a variety of speciﬁc
enzymes in concert with the many androgen receptors.14,15
The best current evidence suggests that AAS
pharmacodynamics mechanisms on muscle tissue are
numerous and varied.7,14,15
The primary AAS mechanism of action involves the
stimulus for DNA transcription.14,15 Once they are available
at the cellular level, the lipid-soluble AAS molecules
diffuse across the cell membrane into the cytoplasm, where
they bind with the intracellular androgen receptors.14,15
These receptor-bound compounds enter the cell nucleus to
bind with DNA, which promotes transcription, thus
Journal of Athletic Training
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Figure 2. Biochemical pathways of the human androgens: androstenediol, androstenedione, dehydroepiandrosterone, dihydrotestosterone, and testosterone.

stimulating protein synthesis.14,15 The AAS also may work
as glucocorticoid antagonists and displace these catabolic
compounds from their receptor sites, thereby limiting the
possible effects of cortisol and related compounds.14 Some
authors14,22 also suggest a possible ergogenic effect of AAS
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through psychotropic actions. Preliminary research indicates that other possible ergogenic actions of AAS require
further study,14 including the downregulation of myostatin,7,23,24 and the possible stimulus to synthesize human
growth hormone and insulin growth factor 1.12

about female hormone replacement therapy (HRT)
contribute to the controversial use of AAS for
‘‘andropause.’’6 A number of systematic reviews and
meta-analyses6,17,18,33 indicate possible beneﬁts, but the
ﬁndings remain inconclusive. Lifestyle, including increased
activity, may limit some age-related negative hormonal
changes without the negative pharmacologic side effects.62
Further study is required before deﬁnitive statements can be
made.18
Other Medicinal Purposes. Although treatment efﬁcacy
remains uncertain, AAS also have been considered and
used in the therapeutic treatment of some cancers (eg,
certain breast cancers) and chronic renal failure, among
other conditions.2,7,16
Figure 3. Chemical structure of testosterone.

Therapeutic Uses of AAS

Certain medicinal uses for AAS are accepted; other
possible health beneﬁts are not currently acknowledged or
accepted by the medical community.1,2,6,7,14,17–19,24,26–33
Pharmacologic uses of AAS for the treatment of diseases
and disorders continue to evolve.1,2,7,14,18,19 Although any
potential therapeutic beneﬁts must not be exaggerated, it is
just as important to not overstate the health risks.14,56
Reproductive Health. Testosterone and its synthetic
analogs have long been considered possible treatment
agents for various male reproductive disorders.1,2,7,16–19,26
Two meta-analyses18,19 suggested that AAS treatment may
be associated with beneﬁts for male sexual function but
cautioned about the somewhat weak results and cited a need
for more well-designed, long-term studies. Additionally,
the authors26 of a systematic review reported that no AASbased male contraceptive was ready for therapeutic use but
encouraged continued research.
Anticatabolism. The AAS have been clinically used to
treat catabolic conditions since the 1940s.7 Generally, the
strongest evidence for anticatabolic AAS efﬁcacy involves
the treatment of severe burn patients.7,24 High-quality
systematic reviews and meta-analyses that addressed
chronic catabolism with AIDS tend to show positive
outcomes for AAS therapy.7,24,27,28 Equivocal results were
demonstrated for AAS use in other wasting conditions,
including chronic obstructive pulmonary disease,7,30,32
wound healing and postoperative recovery,15 and alcoholrelated liver disease.7,24,31 To solidify the efﬁcacy and
safety of therapeutic AAS use for anticatabolism, more
well-designed studies are needed.7,24,28–30
Bone Health. Based on a 2006 systematic review and
meta-analysis 20 on testosterone and bone health,
intramuscular AAS injections moderately improved
lumbar bone density, but the effects on femoral-neck
density were inconclusive. The clinical efﬁcacy of
testosterone to prevent or treat osteoporosis was weak,
although the authors encouraged further study of fractures
and testosterone.
Anti-Aging. With advancing age, male endogenous
testosterone production declines,7,18–20 which has been
suggested by some to underlie many health maladies.17,18
Therapeutic AAS use has increased in middle-aged to older
men as an anti-aging therapy while spurring reviews of
efﬁcacy and safety.6,17,18 Additionally, recent concerns

Ergogenic Effects of AAS

A number of high-quality scientiﬁc papers57–66,130–132
addressed the efﬁcacy of AAS on mass, body composition,
and physical performance (Table 4). Many issues confound
AAS efﬁcacy study designs, thus yielding diverse results.11,13,22,51,52,55,56 Ethical issues aside, institutional
review boards generally do not allow researchers to
duplicate real-world supraphysiologic, polypharmaceutical
dosing regimes.11–13,51,52,55,56 Furthermore, the effectiveness
of participant blinding when studying AAS is questionable.59 Efﬁcacy studies involve many different research
factors, including numerous AAS, varied dosages, assorted
training protocols, dissimilar periods, genetically diverse
participants, dietary variances, and numerous physical
performance measures.11–13,20,51,55,59 The complexity of
AAS efﬁcacy studies makes comparisons and conclusions
difﬁcult.11,20,22,51,55,56,59 Well-designed studies are prospective, placebo controlled, and double blind in nature.20,51
Protocols also must involve random assignment and control
diet and training.20,51 Sample size, participant background,
performance measures, and a crossover design also affect a
study’s overall quality.20,51 After evaluating scores of AAS
efﬁcacy studies according to these criteria, we provide the
following examples of high-quality studies.
AAS Effects on Body Composition. In one early
study130 involving 28 moderately active college-aged
males, participants were randomly assigned to the group
receiving 1.0 mg/kg of nandrolone decanoate in weeks 2, 5,
and 8 or a placebo group. After 9 weeks of progressive
strength training without dietary controls, no changes were
noted in body mass or composition. Another group131
completed a double-blind, placebo-controlled, randomassignment project in which participants received either a
placebo or 75 mg/d (increased to 150 mg/d after 4 weeks)
of mesterolone. All 21 healthy young male participants
completed a high-intensity, progressive resistive training
program throughout the 8-week study. No changes were
seen in body mass for either group, although thigh
circumference increased for the AAS group.131 In a 4week, double-blind, placebo-controlled 1971 study,63 20
collegiate weightlifters were randomly assigned to ingest
10 mg/d of methandrostenolone or a placebo. A signiﬁcant
increase in total body mass occurred, with caliper
measurements suggesting an increase in lean tissue.
Others64 reported that healthy males given daily 5-mg
doses of methandrostenolone increased muscle size
(circumference) and total weight and decreased
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No
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Protein
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Bhasin et al (1996)60

Fahey and Brown (1973)130

Giorgi et al (1999)61

Hervey et al (1981)65

Johnson et al (1972)64

Lichtenbelt et al (2004)57

O’Shea (1971)63

Rogerson et al (2007)59

Storer et al (2003)66

Stromme et al (1974)131
21

54

16

20

16

31

7

21

28

40

52

25

Participants,
N

21–27

18–35

21–35

19–26

19–44

18–38

25–38

19–45

College

19–40

60–75

20–30

Age, y

3 d/wk 3 8 wk

None

2–3 d/wk 3 6 wk

3 d/wk 3 4 wk

8 wk

3 d/wk 3 3 wk

Variable for 6 wk

4 d/wk 3 12 wk

3 d/wk 3 8 wk

3 d/wk 3 10 wk

20 wk

7 d/wk 3 4 wk
(endurance)

Training

10 mg/d methandrostenolone
10 mg/d placebo
control
200 mg/wk nandrolone decanoate
200 mg/wk placebo
10 mg/d methandrostenolone
10 mg/d placebo
3.5 mg/kg/wk testosterone enanthate
3.5 mg/kg/wk placebo
25 mg/wk testosterone enanthate
50 mg/wk testosterone enanthate
125 mg/wk testosterone enanthate
300 mg/wk testosterone enanthate
600 mg/wk testosterone enanthate
75 mg/d 3 4 wk to 150 mg/d 3 4 wk mesterolone
75 mg/d 3 4 wk to 150mg/d 3 4 wk placebo

100 mg/d methandienone
100 mg/d placebo

3.5 mg/kg/wk testosterone enanthate
3.5 mg/kg/wk placebo

300 mg/wk 19-nor-4-androstenedione
240 mg/wk testosterone undecanoate
900 mg/wk placebo
25 mg/wk testosterone enanthate
50 mg/wk testosterone enanthate
125 mg/wk testosterone enanthate
300 mg/wk testosterone enanthate
600 mg/wk testosterone enanthate
600 mg/wk placebo w/o exercise
600 mg/wk placebo w/exercise
600 mg/wk testosterone enanthate w/o exercise
600 mg/wk testosterone enanthate w/exercise
1 mg/kg 3 3 wk nandrolone decanoate
1 mg/kg 3 3 wk placebo

Study Groups

 Thigh circumference
Ø Maximal strength, mass, V̇O2max, free
testosterone
 Testosterone (plasma-bound, total)

 Mass, leg press, bench press (1RM)
 Cycle sprint (peak power, total work)
 Dose-dependent leg press, leg power (1RM)
Ø Muscle fatigability, specific tension

 Mass, squat, bench press (1RM)

 Mass (total, fat free), body mass index

 Bench press, squat (1RM)
 Fat-free mass, triceps and quadriceps size
 Testosterone (free)
 FSH, LH, SHBG
Ø Body composition, anthropometrics
Ø Bench press, dead lift (1RM)
Ø Maximal aerobic capacity, peak work
 Bench press (1RM), mass, lean mass
 Arm girth, rectus femoris circumference
 Abdominal skinfold thickness
 Mass, lean mass, limb circumferences, muscle
widths
 Total potassium, total nitrogen, leg strength
Ø Arm or hand strength, fat and subcutaneous
fat
 Dynamic and static strength, mass, limb size
Ø V̇O2max, sperm count, subcutaneous fat

Ø Serum: AST, creatine kinase, urea
Ø Urine: adrenaline, noradrenaline, dopamine
Ø Treadmill running: maximum, submaximum
 Leg press (1RM)
 Lean mass, triceps and quadriceps size
 Testosterone (free, total)
 FSH, LH

Outcomes

Abbreviations: Ø, no changes;  increase; , decrease; 1RM, 1-repetition maximum; AST, aspartate aminotransferase; FSH, follicle-stimulating hormone; LH, leutinizing hormone; SHGB,
sex-hormone-binding globulin; w/o, without.

Yes

No

Diet
Controlled?

Bhasin et al (2005)58

Baume et al (2006)

132

Author(s) (Year)

Table 4. Selected High-Quality Studies on Anabolic-Androgenic Steroid Efficacy

subcutaneous adipose tissue compared with the placebo
group. Authors of a 1981 study65 reported the effects of 100
mg/d of methandienone on 7 male weightlifters. The
double-blind, placebo-controlled study involved a
crossover design, including two 6-week periods with a 6week washout. Participants gained weight during the AAS
periods, although body fat did not vary.
A well-designed and well-controlled 1996 study60
investigated the effects of a 600-mg weekly dose of
testosterone enanthate or placebo on body mass and
composition. A total of 40 young, healthy participants
completed the 30-week study, which consisted of 4 weeks
of a control period, 10 weeks of treatment, and 16 weeks of
recovery. This double-blind study involved 4 randomly
determined groups: placebo without training, placebo with
training, AAS without training, and AAS with training. The
researchers also controlled protein and total caloric intake.
Mean weight in the placebo groups did not change but
increased in both AAS groups; the AAS-with-training
group gained signiﬁcantly more weight than the AASwithout-training group. Additionally, except for the placebo-without-training group, all groups gained lean mass.
Finally, muscle cross-sectional area increased for both AAS
groups; the AAS-with-training group achieved the greatest
gains.60
A 2004 double-blind, randomized study57 of 16 experienced bodybuilders involved weekly injections of nandrolone decanoate or a placebo (200 mg) for 8 weeks.
Participants continued training at their normal levels. The
AAS group increased total body mass and relative lean
tissue compared with the placebo group.
Authors of a 1999 study61 reported weight and size (ie,
girth) increases for strength-training participants given
testosterone enanthate compared with a placebo. After
random assignment, 21 young, healthy males completed 12
weeks of double-blind drug or placebo (weekly doses of 3.5
mg/kg) and strength-training intervention. Weight and size
increases reverted to normal 12 weeks after the drug
intervention.61
One 2005 paper58 detailed a 36-week prospective study
of testosterone enanthate and gonadotropin-releasing hormone agonists on 60 healthy, older (60–75 years) men.
During the 20-week treatment period, participants received
weekly injections of doses ranging from 25 to 600 mg,
depending on their random group assignment. Participants
did not strength train or complete moderate to intense
aerobic exercise during the study. A positive, dose-related
response with regard to lean mass increases and an inverse
dose-response relationship to fat mass were observed.
Finally, 16 healthy collegiate men enrolled in a 2007
placebo-controlled, double-blind study59 to investigate, in
part, the effects of AAS on body mass and composition.
Researchers randomly assigned participants to receive
weekly injections of either testosterone enanthate or
placebo. All trained for muscle hypertrophy during the
trial. The AAS group gained more mass than the placebo
group.59
Overall, the best science related to the effects of
exogenous, nontherapeutic abuse of AAS on body composition suggests a dose-related potential for increased
relative lean body mass.57–61
AAS Effects on Physical Performance. Even though
evidence suggests possible increased lean mass with AAS

abuse,57–61,63–65 more muscle does not always equal
improved performance. In some endeavors, such as
marathons and triathlons, increased mass (lean or
otherwise) may lead to a performance decrease.
Considering the known association between muscle mass
and force development, a relationship between AAS
abusers and strength or power activities, although not
necessarily causal, is not unexpected.
The authors of an early study63 investigated methandrostenolone use at 10 mg/d and resistance training by
university students over 4 weeks. All participants ingested
a high-protein supplement. The protocol involved a
randomized, double-blind, placebo-controlled design.
Training with AAS increased performance in the 1repetition maximum (1RM) bench press and squat. Others64
studied the use of 10 mg/d of methandrostenolone and a
protein supplement by college students. This randomized,
double-blind, placebo-controlled study lasted 7 weeks,
including the 3-week treatment phase. Participants trained
3 times per week at increasing intensities. The authors
reported increases in 1RM bench press and squats by the
treatment group over both the placebo and control groups.
A 1973 paper involved a randomized, double-blind,
placebo-controlled study on AAS efﬁcacy in 28 healthy
males.130 Throughout the 9-week study, participants
strength trained 3 days per week using progressive
resistance. Participants received 1.0 mg of nandrolone
decanoate or saline solution per kilogram of body weight
during weeks 2, 5, and 8. This study did not control for diet,
nor did it supplement with additional protein. No signiﬁcant
gains were seen in the AAS group over the placebo group
for any performance indicators, including 1RM bench press
and dead lift, as well as all isokinetic peak torques for
elbow, shoulder, and knee ﬂexion-extension movements.
Other investigators131 designed a double-blind, placebocontrolled prospective study involving 21 healthy college
students. Random assignment was to either the mesterolone
or placebo group. Drug dosage increased from 75 mg/d to
150 mg/d midway through the 8-week study. The authors
controlled a progressively increasing, high-intensity training program. Dietary protein (30 g/d) was supplied to both
groups throughout the study. Performance measures
included maximal isometric force for 4 motions (elbow
ﬂexion, trunk ﬂexion, trunk extension, and knee ﬂexionextension). No differences were seen between the AAS and
placebo groups.
A 1981 prospective, randomized, double-blinded, placebo-controlled, and crossover study consisted of 7 healthy,
young weight lifters.65 Two treatment periods (100 mg/d of
methandrostenolone) of 6 weeks were separated by 6 weeks
of drug washout. Progressive resistance training occurred
over the full 18 weeks. Gains were observed in leg strength
(isometric dynamometry similar to the dead lift) but not
with the isometric shoulder press or hand grip.
More recently, a few well-designed AAS efﬁcacy studies
were conducted in healthy, eugonadal participants.59–
61,66,132
One group60 examined the effects of 600 mg/wk
of testosterone enanthate on 40 experienced male weight
lifters, ages 19 to 41 years. Participants were assigned to 1
of 4 groups: testosterone with exercise, testosterone without
exercise, placebo with exercise, and placebo without
exercise. The authors controlled diets, and all participants
consumed 1.5 g of protein per kilogram of body weight.
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Training consisted of supervised, moderate-intensity weight
training 3 days per week for 10 weeks. Participants in the
testosterone-with-exercise group experienced the greatest
performance gains, as measured by 1RM bench press and
squat. The testosterone-without-exercise and placebo-withexercise groups also gained strength when compared with
the placebo-without-exercise group.60
A 1999 study61 prospectively investigated the effects of
3.5 mg/kg of testosterone enanthate over 12 weeks of
strength training by 21 healthy, active males in a doubleblind trial. After random assignment, participants completed a 4-d/wk, periodized, whole-body strength-training
program determined by their individual baselines. Gains
occurred in the 1RM bench press for those receiving the
testosterone injections compared with the placebo group.
Twelve weeks of follow-up training without injections
resulted in a return of the measure to that of the placebo
group.61
In a prospective, 20-week 2003 study,66 61 young,
healthy males with prior resistance training experience
were randomly assigned to 1 of 5 treatment groups
receiving weekly testosterone enanthate injections: 25 mg,
50 mg, 150 mg, 300 mg, or 600 mg. They did not train
during the treatment period. Daily energy intake involved
150 kJkg1d1, including 1.3 g/kg of protein. A dosedependent increase in leg-press strength and power was
observed.
Authors59 of a 2007 paper reported ﬁndings of a 6-week,
randomized, double-blind, placebo-controlled investigation
of 16 young, healthy males. Participants received 3.5 mg of
testosterone enanthate or saline per kilogram of body
weight each week for 6 weeks and performed a structured
heavy-resistance training protocol throughout the trial.
Living conditions were also controlled, and participants
consumed standardized meals that included protein supplementation. The experimental group’s 1RM bench press and
total work values during a 10-second cycle sprint were
improved at 3 and 6 weeks.59
A well-designed project132 looked at the efﬁcacy of AAS
as related to endurance performance. Twenty-four young,
active, healthy male volunteers participated. After initial
testing to determine running velocity at individual anaerobic thresholds, they completed personalized 4-week
training protocols designed to improve this measure and
during that time ingested 300 mg/wk of 19-nor-4androstenedione, 240 mg/wk of testosterone undecanoate,
or 300 mg/wk of placebo. The study was randomized and
double blinded. Anaerobic threshold velocities did not vary
either before or after treatments. Although all groups
improved their running velocity at anaerobic threshold after
4 weeks of AAS use and training, neither of the
experimental groups (19-nor-4-androstenedione or testosterone) improved more than the placebo group.
Last, many recent scientiﬁc investigations involved the
use of AAS for HRT among older adults or hypogonadal
participants. Dozens of published papers examined the
effects of HRT on a variety of variables, including
muscular performance.6,62 The HRT ﬁndings were summarized in a meta-analysis6 and a systematic review.62 In their
2006 meta-analysis6 of 11 prospective studies, the authors
suggested a ‘‘moderate increase in muscle strength’’ with
HRT in elderly men. In a systematic review62 of various
sarcopenia treatments, the authors concluded that male
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HRT produced moderate strength increases, although not
all protocols were successful.
Health Effects of AAS

Some56 have suggested that AAS abuse risks are
exaggerated, but others72,73,133,134 proposed that supraphysiologic AAS abuse negatively affects human health,
even to the point of premature death. Therapeutic AAS use
helps to resolve speciﬁc health maladies,6,7,13,18–20,24,26–33
but like all medicinal agents, AAS also have side effects
(Table 5). Making deﬁnitive claims concerning the effects
of long-term, high-dose, multidrug AAS abuse is difﬁcult
because researchers cannot ethically administer such
protocols.11–13,51,52,55,56 These scenarios have never been
and may never be duplicated in a controlled research
setting.22,51,52,55,56 With AAS abuse, as with those seeking
improved performances or physiques, the negative effects
appear to increase, thus presenting health risks.
Effects of AAS Abuse on the Central Nervous System.
Supraphysiologic doses of AAS are associated with a
variety of neuropsychological effects. The best established
of these effects are AAS-associated mood disorders, AAS
dependence syndromes, and progression from AAS to other
forms of substance abuse and dependence.
AAS-Associated Mood Disorders. A growing body of
literature indicates that markedly supraphysiologic doses of
AAS may cause hypomanic or manic syndromes in some
individuals.21,54,67–78 These syndromes involve euphoric or
irritable mood, exaggerated self-conﬁdence (which may
occasionally result in grandiose delusions), decreased need
for sleep, hyperactivity (including sexual hyperactivity),
and reckless or sometimes violent behavior.67 However,
these syndromes are idiosyncratic. Most AAS abusers, even
when using high doses, do not display major mood
disturbances, although a minority may exhibit dramatic
changes, with behavior completely different from their
baseline personalities.21 We have no clear way to predict
who will and will not develop these syndromes. Hypomanic
syndromes may occur in individuals without a history of
mood disorder or personality disturbance.21
Some evidence suggests an association between AAS
dose and the risk of manic or hypomanic episodes. For
example, laboratory studies using only modestly supraphysiologic doses of testosterone or equivalent AAS (up to
300 mg/wk, representing 4 to 6 times normal male
endogenous testosterone production) have rarely found
clinically signiﬁcant mood disorders among participants.21
Similarly, among illicit AAS abusers, mood disorders
rarely appeared in individuals taking the equivalent of 300
mg/wk of testosterone135 and are uncommon even in those
taking the equivalent of 300 to 1000 mg/wk.21,68 However,
these disorders occur at increased frequency among men
taking doses of more than 1000 mg per week.68 In women,
AAS abuse is rare, and indeed, in only 1 study69 in the past
15 years have investigators successfully recruited and
interviewed female AAS abusers. Among the 25 AASabusing participants, none met the diagnostic criteria for
hypomanic or manic syndrome, although some described
feelings of euphoria, irritability, or increased libido.69
The lay press commonly refers to AAS-induced mood
syndromes by the popular term roid rage, implying that
aggressive or violent behavior is a central feature. Although

Table 5. Possible Anabolic-Androgenic Steroid Abuse Health Effects
System

Possible Adverse Effects

Cardiovascular

Cardiac dysfunction:  left ventricle peak ejection fraction, systolic strain, early diastolic peak velocities, E/A
ratio, right ventricle function
Major mood disorders, dependence, progression to other forms of substance dependence
 total cholesterol, low-density lipoproteins;  high-density lipoproteins
Cholestatic hepatis, cholestatic jaundice, peliosis hepatis, adenomas, carcinomas
General immunosuppression:  antibody synthesis, B- and T lymphocyte maturation, natural killer cell
activity; systemic infection (from needle, syringe misuse)
Sebaceous gland hypertrophy,  sebum and skin lipid excretion,  acne, seborrhea, striae distensae,
hypertrichosis, hirsutism, rosacea, folliculitis, keloids, furunculosis

Central nervous
Hematologic
Hepatic
Immune
Integumentary
Neuroendocrine
Male
Female
Musculoskeletal
Nephritic
Oral

Hypothalamic-pituitary-testicular axis suppression, hypogonadism, testicular atrophy, sexual dysfunction,
infertility, gynecomastia, male-pattern baldness, libido changes, prostate hypertrophy, cancer
General virilization, hirsutism, voice deepening, male-pattern baldness, clitoral hypertrophy, breast
reduction, menstrual dysfunction, libido changes
Premature epiphyseal closure, tendinopathies
Kidney stones, cholestasis, tubular necrosis, hyperbilirubinemia, proteinuria, focal segmental
glomerulosclerosis, renal cell cancer, Wilms tumor
Gingival hypertrophy,  temporomandibular dysfunction

Abbreviations: , increase; , decrease; E/A ratio, the ratio of passive ventricle filling (early [E] wave) and active filling with atrial systole
(atrial [A] wave).

a colorful term, roid rage has no agreed scientiﬁc meaning.
Nevertheless, AAS-induced hypomanic and manic syndromes often are associated with irritable or aggressive
behavior.21 In some, this behavior may rise to the level of
outright violence, and the victims are often women.70
Several case reports21 have described individuals who
committed violent crimes while using AAS. Some of them
had no history of violence, no criminal records, and no
evidence of psychiatric disorder before AAS exposure,
suggesting that the observed behavior was attributable to a
biological AAS effect. The authors71 of a literature review
on AAS-induced aggression suggested that this phenomenon is sufﬁciently well documented to meet the so-called
Daubert criteria, as a scientiﬁcally accepted event admissible in court testimony.
Various forensic studies suggest an association between
AAS abuse and violent or criminal behavior.72–76 These
include case series, describing unusual violence among
young AAS abusers74; epidemiologic data suggesting both
a possible link between AAS abuse and death by homicide
or suicide72,73 and a relationship between AAS abuse and
conviction for weapons offenses.76 It is important to note
the direction of causality cannot be determined in such
studies; it may be that AAS abuse predisposes individuals
to violent behavior, that violent individuals are more
predisposed to AAS abuse, or both.
This issue of causality raises the more general question of
whether AAS-associated manic syndromes are attributable
to a biological effect of AAS themselves, as opposed to
underlying personality attributes of the abuser or psychosocial factors surrounding AAS abuse.21,71,136 One might
argue that individuals who abuse AAS are inherently more
prone to aggression or, alternatively, that expectations may
prompt individuals to behave aggressively, even in the
absence of an actual biological effect. However, in several
prospective, randomized, double-blind, placebo-controlled
studies,54,77,78 investigators administered supraphysiologic
doses of AAS to normal volunteers and demonstrated
hypomanic effects in some participants, suggesting that
these effects cannot be entirely explained by psychosocial
factors. Speciﬁcally, among 109 men in 4 studies who

received doses of at least 500 mg/wk of AAS under blinded
conditions, 5 (4.6%) developed hypomanic or manic
syndromes on AAS, but none developed these syndromes
on placebo.54 This ﬁgure is likely an underestimate of the
true prevalence of hypomanic or manic episodes among
AAS abusers, who frequently receive much larger doses.21
Abusers of AAS typically use several AAS simultaneously,1,4,8,9,21,41,45 thus possibly further increasing their psychiatric vulnerability. Finally, these studies generally excluded
participants with preexisting psychopathology, whereas
AAS abusers do not similarly screen themselves.
Other lines of evidence also suggest that AAS-associated
mood syndromes cannot be entirely explained as the result
of premorbid personality factors or expectations. For
example, 3 reports collectively described 4 monozygotic
twin pairs in which 1 twin abused AAS and the other did
not.137–139 In each case, the AAS-abusing twin exhibited
prominent AAS-associated symptoms, including suicide in
1 case139 and extreme violence in another.138 None of the
non–AAS-abusing twins exhibited any signiﬁcant psychopathology.137–139 The AAS also induce aggression in rodent
models,50,140 again suggesting a biological component in
these effects. However, the reasons for individual variability (in both humans and animals) remain unclear.
Evidence from naturalistic studies also suggests that
episodes of major depression may arise in AAS abusers,
especially during withdrawal.79 These depressive symptoms
may be partially attributable to suppression of the
hypothalamic-pituitary-testicular axis by AAS.7,11–14,22,51
As in hypomanic syndromes, depressive episodes appear to
be highly idiosyncratic, with many individuals exhibiting
virtually no depressive symptoms during withdrawal and
occasional individuals becoming profoundly depressed and
even suicidal.80 Again, the reasons for this variability are
unknown.
For largely ethical reasons,11–13,23,52,55 no laboratory
studies have been conducted on the withdrawal effects
from supraphysiologic AAS doses. It is, of course,
unethical to administer massive, prolonged AAS doses to
normal volunteers and then deliberately precipitate withdrawal. Thus, evidence regarding these depressive effects
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necessarily stems almost entirely from naturalistic investigations and is subject to all related limitations, such as
selection bias, recall bias, and the presence of confounding
variables.84 Yet laboratory investigations of normal volunteers suggest that pharmacologically induced hypogonadism may indeed be associated with depressive reactions that
occur idiosyncratically in some individuals.81
AAS Dependence. Increasingly acknowledged is that
some AAS abusers develop a syndrome of AAS dependence.82,83 To date, 8 ﬁeld studies conducted in the United
States, Great Britain, and Australia have collectively noted
AAS dependence in 197 (30.2%) of 653 AAS abusers.82
Even if one was to assume an estimate of much less than
this 30% ﬁgure, it would follow that there are still hundreds
of thousands of AAS-dependent Americans and millions
more worldwide who have consumed AAS for prolonged
periods, often despite adverse medical, psychiatric, and
social consequences. Dependence on AAS may arise via
any or all of 3 possible mechanisms: anabolic, androgenic,
or hedonic.84 The anabolic mechanism refers to the musclebuilding effects of AAS, which may be particularly
appealing to men (and, in rare cases, women) with bodyimage disorders who wish to look leaner and more
muscular.84 Some individuals experience a syndrome
termed muscle dysmorphia, or reverse anorexia nervosa,
a form of body dysmorphic disorder in which individuals
become preoccupied with their perceived lack of muscularity.141 People with this form of body dysmorphic
disorder may be particularly at risk for repeated AAS
abuse because they constantly strive to be bigger.85,86
Paradoxically, however, some individuals develop worsening symptoms of muscle dysmorphia with AAS abuse,
perhaps because they become increasingly preoccupied
with their muscularity.84 Thus, they may continue to repeat
AAS cycles, afraid of the possibility of losing even a little
muscle size if they discontinue the drugs. Published
descriptions of such individuals suggest this phenomenon
is quite similar (albeit in reverse) to classical anorexia
nervosa, in which the patient experiences severe anxiety
about the prospect of gaining even a pound.142 Additionally, athletes may be further disposed to muscle dysmorphia
and related body-image concerns due to pressures to be and
appear athletically competent. This may encourage many to
train with the dual intents of improving both performance
and appearance. As such, some may decide to abuse AAS
to achieve not only their athletic demands but also their
psychological expectations.143
In susceptible individuals, AAS dependence may be
further potentiated by the androgenic effects whereby these
drugs affect the abuser’s own endocrine function. Specifically, men who abuse AAS for prolonged periods may
profoundly suppress their hypothalamic-pituitary-testicular
functioning, to the point that protracted AAS-withdrawal
hypogonadism develops every time they stop AAS.84,87
This hypogonadism, as mentioned earlier, may be associated with depression or with other symptoms, such as loss
of sex drive and fatigue.144 Therefore, these individuals
may soon be tempted to resume AAS to abort these
dysphoric effects and may eventually develop a pattern of
continuous AAS abuse.
It now appears that AAS dependence may evolve by a
third pathway in a mechanism similar to that of classical
drug addiction.84,88 Documentation of this hedonic pathway
580
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has occurred in laboratory animals. For instance, rodents
will self-administer testosterone, even to the point of
death142; some evidence suggests that this self-administration process may be at least partially mediated by
opioidergic mechanisms.89 A similar process likely occurs
in humans. It is notable that AAS-dependent humans often
report other forms of classical substance dependence,
indicating that certain individuals may have an innate
susceptibility to substance-dependence syndromes in general, including dependence upon AAS.82 Clinical observations suggest that AAS dependence, as it evolves, may
increasingly resemble classical substance dependence in its
behavioral manifestations. In particular, AAS abuse and the
surrounding lifestyle of the ‘‘gym culture’’ may become the
central focus of an individual’s life.145
Progression to Other Forms of Substance Dependence. Results from several studies suggest that AAS
abusers may be prone to develop other forms of drug
dependence, especially opioid dependence.83,90–93 For
example, 40 (64%) of 62 male AAS abusers recruited in
the ﬁeld reported a lifetime history of some form of illicit
drug dependence other than AAS.83 In another investigation, 21 (9%) of 227 sequentially admitted male heroin
addicts appeared to have been ﬁrst introduced to opioids via
AAS abuse.91 Similarly, among 88 men with a primary
diagnosis of opioid dependence, 22 (25%) reported prior
AAS abuse, as compared with only 7 of 135 (5%) men with
other forms of substance dependence (P , .001).90
Notably, recent observations indicate that AAS abusers
may develop other forms of substance dependence before,
during, or after their AAS abuse83,92; AAS abuse may not
necessarily predispose an individual to other forms of
substance dependence, but these various forms of drug
abuse may arise from a common underlying susceptibility,
as mentioned earlier.
Effects of AAS Abuse on the Cardiovascular System.
A growing literature, including anecdotal reports, animal
trials, clinical studies, and comprehensive reviews,
describes possible adverse cardiovascular effects of AAS
abuse. 6 7 , 9 4 – 9 7 The mechanisms of AAS-induced
cardiovascular toxicity remain uncertain, although one
group98 proposed that AAS may be directly toxic to
cardiac tissue, resulting in a cardiomyopathy characterized
by decreased myocardial compliance.
Myocardial function studies in AAS abusers, using
sensitive tissue Doppler imaging and strain imaging,
documented marked cardiac deﬁcits in AAS abusers.96,99,100
For instance, AAS abusers had lower early and late
diastolic tissue velocities and reduced peak systolic strain
versus nonusers.96 Other authors100 reported similar impairment of diastolic function in 6 AAS abusers, and tissue
Doppler imaging showed impaired right ventricular function in AAS-using weight lifters.99 A recent US study
compared 12 long-term AAS abusers and 7 non–AAS-using
weight lifters matched for age and exercise history and,
alarmingly, found cardiac deﬁcits in the former group.101 In
particular, AAS abusers showed strikingly lower left
ventricular ejection fractions and strain measures, together
with evidence of diastolic impairment, as illustrated by
markedly lower early versus late diastolic transmitral
blood-ﬂow velocities (ie, a reduced ratio of early to late
ventricular ﬁlling velocity).101 As such, cardiotoxicity from

long-term AAS abuse may be more serious than previously
recognized and may increase the risk for heart failure.101
The cardiovascular effects of AAS are not limited to the
myocardium, as evidenced by a number of studies and
summarized in 3 systematic reviews or meta-analyses.25,94,95 The evidence indicates that AAS abuse increases
low-density lipoprotein cholesterol and decreases highdensity lipoprotein cholesterol: a lipid proﬁle recognized as
a major risk factor for coronary heart disease.25,95,102
However, despite the well-documented changes in circulating lipids caused by AAS, direct evidence that AAS
causes atherosclerosis remains limited, albeit suggestive.55,103 These effects are a concern because widespread
AAS abuse is a relatively recent phenomenon.3,8,9,34–47,49,128
Thus, most long-term illicit AAS abusers are not yet 50
years old and may soon display increasing rates of cardiac
problems as they age.67
Effects of AAS Abuse on the Hepatic System. The abuse
of AAS may occasionally be associated with liver
abnormalities, such as cholestatic hepatis, cholestatic
jaundice, peliosis hepatis, and liver adenomas and carcinomas.7,11–14,22,24,51,55,104 These effects are rare and occur almost
entirely from the abuse of oral C17a-alkylated AAS (ie,
methyltestosterone, oxymetholone, ﬂuoxymesterone,
norethandrolone, methandienone). 7,12,24,55,102,104 The
frequency of AAS-induced hepatic abnormalities may be
overestimated because many liver function tests involve
enzymes present in muscle, which may be elevated from
muscular trauma after high-intensity training. 5 1
Consequently, to test for genuine liver abnormalities
possibly attributable to AAS abuse, it is critical to assess cglutamyl transpeptidase because this enzyme is present in
liver but not in muscle tissue.51 Although it may take an
extended time, many AAS-induced liver conditions appear to
resolve after AAS disuse.12,22,24,51
Effects of AAS Abuse on the Neuroendocrine System.
Abuse of AAS suppresses the hypothalamic-pituitarytesticular axis in males. 7,11–14,22,51 The resulting
hypogonadism is thought to relate to AAS dosage, the
speciﬁc agent abused, and the duration of abuse.11
Hypogonadism can lead to testicular atrophy,7,11–14,22,51,55
sexual dysfunction,11,12,51,55 and infertility.7,11–13,22,51,55
Many of these conditions appear to be reversible upon
cessation, although complete resolution may take more than
1 year.7,11–13,22,51,55
Other possible male endocrine effects of AAS abuse
include gynecomastia due to AAS conversion to estrogens,
which typically requires surgical intervention because
cessation does not reverse this change.11–14,22,51,55 Irreversible male-pattern baldness is another potential side effect as
testosterone is converted to dihydrotestosterone.11–14,22,51,55
Effects on the prostate gland include hyperplasia, hypertrophy, and possibly cancer.11,12,55 As shown in a metaanalysis,17 therapeutic AAS use in middle-aged to older
men led to an increased number of prostate problems.
Well-designed research involving female use of AAS is
limited.51 Abuse of AAS in females apparently leads to
increased masculinization, including voice deepening,
hirsutism, male-pattern baldness, clitoral hypertrophy, and
breast reduction.11–14,22,51 Related changes often seen in
females include acne and changes in libido and menstruation.11,12,14,22,51 Some changes in females appear to be

permanent.12,14,22 One review12 suggested that AAS abuse
may lead to birth defects.
Limited evidence11,12,22 indicates that AAS abuse may
inﬂuence thyroid function, with possible decreased production of triiodothyronine (T3), thyroxine (T4), and thyroidbinding globulin and increased production of thyrotropin
and free T4. The clinical relevance of possible thyroid
changes is presently unclear.12 Moreover, AAS abuse may
decrease glucose tolerance and increase insulin resistance
in humans.12,22,105
Effects of AAS Abuse on the Musculoskeletal System.
Skeletally immature individuals who abuse AAS risk
decreased adult height due to premature epiphyseal
closure.11,12,14,22,51 Further evidence suggests a potential
link between AAS abuse and assorted musculoskeletal
conditions, including various tendinopathies and tendon
ruptures.7,11–13,22,51 Possible causes include relative tendon
versus muscle weakness and actual collagen ﬁber
dysplasia.7,11–13,22,51 The use of AAS for sport injury
recovery has limited support in the literature. Most
wound-healing studies were of burn patients,7 but one
group 106 did report improved recovery time with
therapeutic doses of AAS after induced muscle contusions
in rats. Further study is needed.
Effects of AAS Abuse on the Other Biologic Systems
and Areas. Additional health effects on other human
biologic systems or regions may result from AAS abuse.
Immune System. Literature reviews of both animal and
human studies suggest that immune system changes depend
on AAS dose and type, but AAS generally act as
immunosuppressants.107 Speciﬁcally, AAS appear to decrease antibody synthesis, limit T- and B-lymphocyte
maturation, and diminish natural killer cell activity.11,22,107
Additionally, unhygienic needle or syringe use may lead to
local abscesses or systemic infections, including human
immunodeﬁciency and the hepatitis viruses.11,12,14,22
Integumentary System. Nontherapeutic abuse of AAS
affects various aspects of human skin.11,12,14,22,108,109 Two
reviews108,109 summarized the possible deleterious effects
of high-dose AAS abuse related to the integumentary
system. High doses of AAS promote the hypertrophy of the
sebaceous glands and production of sebum and skin surface
lipids and increase the concentration of Propionibacterium
acnes. These changes increase the risk for conditions such
as acne (conglobata, vulgaris, or fulminans), seborrhea,
striae distensae, hypertrichosis, hirsutism, rosacea, folliculitis, keloids, and furunculosis.108,109 Furthermore, preexisting dermatologic conditions may be exacerbated by AAS
abuse, including psoriasis, rosacea, angiolipomatosis, and
acne vulgaris.108
Nephritic System. Although less studied and reported,
renal side effects may occur with AAS abuse.11,22,51,55,110,111
Possible nephrologic conditions include kidney stones,
cholestasis, tubular necrosis, hyperbilirubinemia, proteinuria, focal segmental glomerulosclerosis, renal cell cancer,
and Wilms tumor.11,51,55,110,111 The pathophysiology of
AAS-induced kidney conditions is unclear.110 Complicating
factors in athletic and active individuals may include the
frequent use of nonsteroidal anti-inﬂammatory agents,
nutritional supplements, high-protein diets, and dehydration
(purposeful or otherwise).110,111
Oral Region. Limited research suggests a possible
association between AAS abuse and maladies related to
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the gingival tissues52 and masticatory system.112 A
preliminary paper52 indicated that prolonged AAS abuse
led to gingival tissue enlargement, including signiﬁcantly
thicker gingival tissue, gingival encroachment, and total
gingival enlargement scores compared with AAS nonusers.
These changes sometimes require surgical intervention.52
Another study112 indicated that AAS abuse may play a role
in altering the masticatory structures, thus increasing the
incidence of temporomandibular dysfunction.
AAS Abuse Prevention

Individuals typically abuse AAS to gain performance
advantages and enhance their physique or body image (or
both).1,2,4,5 The abuse of AAS often begins during
adolescence,35,36,41–43,46,47 and thus prevention strategies
should also begin at a young age. Prevention techniques
generally include educational or screening paradigms (or
both). Although relatively few scholarly publications
speciﬁcally address AAS abuse prevention, general drug
abuse prevention requires detailed understanding, including
resistance skill development, learning peer norms, and
being involved in a multisubstance abuse prevention
program that does not focus solely on one substance of
abuse. Using related theory in prevention efforts may be
clinically helpful. For example, the transtheoretical model
helped to explain and address smoking behaviors in speciﬁc
populations and may also apply to AAS abuse.125,126
Understanding the reasons for AAS abuse or intent to
abuse, as well as abuse progressions, may be an effective
AAS prevention strategy in conjunction with other
prevention initiatives.125,126
Drug Testing for AAS Abuse Prevention. Over the past
half century, screening for general drug abuse evolved as
part of prevention programs. Drug-tested groups are many
and varied: for example, military personnel, civilian and
governmental employees, and amateur and professional
athletes. For some testing agencies, AAS are not drugs of
interest, but the more common screening is for illicit abuse
of recreational and other prescription drugs. Athlete AAS
testing began more than 30 years ago.1,4,5 Testing for AAS
typically involves only organized, competitive sport
participants and thus is generally not targeted at the
noncompetitive ﬁtness or bodybuilding population.146
Screens for AAS initially focused on elite athletes but
have since evolved to include collegiate and some high
school student-athletes. 114 Numerous international,
national, and regional bodies oversee sport AAS
testing.113 The World Anti-Doping Agency and related
national organizations have strict, year-round, no-notice,
accredited-laboratory drug testing, whereas other programs
are less stringent and sometimes limited by collective
bargaining agreements.4,113 Although these programs are
varied, expensive, and time intensive, their effectiveness as
preventive measures remains unclear.114 The many inherent
testing variables make conducting related studies and
drawing appropriate conclusions challenging.
The authors of one early study115 reported that more
frequent drug testing resulted in a gradual decline in the
number of positive drug tests for Norwegian athletes from
1977 to 1995. Only one group114 conducted a prospective
randomized controlled study to investigate the deterrent
efﬁcacy of AAS testing for adolescent athletes. Student582
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athletes (N ¼ 1396) from 11 high schools (5 drug testing, 6
controls) completed the 2-year project. Using a method
similar to that used for out-of-competition Olympic testing,
the investigators found that AAS abuse remained unaffected over a 2-year period. In addition, those high school
student-athletes randomized to testing had increased risk
factors for future drug abuse. No known prospective
randomized trials exist to demonstrate the deterrent efﬁcacy
or inefﬁcacy of AAS abuse testing in other populations
such as collegiate, professional, or Olympic athletes. With
only 1 well-designed study investigating AAS screening in
a very speciﬁc population,114 the overall deterrent efﬁcacy
of such testing remains understudied and unclear. Additional research on the deterrent effect of AAS testing is
greatly needed.
Education for AAS Abuse Prevention. When
implemented as a stand-alone intervention, AAS testing
focuses on identifying the abuser, but health care
professionals should also be concerned about identifying
the potential AAS abuser. This paradigm involves
education of not only AAS abusers but also potential
abusers, educators, and medical professionals.
Numerous authors investigated educational programs as a
preventive measure for AAS abuse.114,116–120,147 One 2004
European group120 reported positive results after the
implementation of a health promotion program to prevent
AAS misuse among adolescents. The 2-year teaching
session and group-discussion intervention program focused
on appearance and self-conﬁdence, rather than AAS abuse.
Group discussions included both sexes. Results indicated
that AAS abuse in adolescent boys, ages 16 through 17
years, might decrease after an educational program focused
on appearance and self-conﬁdence, although the authors
recommended further study. Another project by this
group120 emphasized the varied attitudes between AAS
abusers and AAS nonusers and the need to understand these
differences in designing an effective prevention program.
For example, understanding is limited about the many
reasons for AAS abuse, such as body-image enhancement,
improved performance, and others. Gaining insight into the
phenomenologic patterns of AAS abuse warrants further
study. Similar to eating disorder prevention and screening
protocols, simple body-image screening instruments may
need to be included during the preparticipation physical
examination process or during neuropsychological testing
to help identify those more at risk for AAS abuse.
One US-based research group147,148 developed and tested a
number of AAS prevention protocols for adolescents. An
early study147 suggested that educational interventions
stressing solely the negative effects of AAS were not only
ineffective but increased adolescents’ desire to abuse
androgens. Programs focusing on knowledge of risks and
beneﬁts of AAS improved knowledge but did not change
attitudes toward abuse; thus, they were deemed ineffective
prevention approaches.148 Since then, the authors have
developed team-centered, sex-speciﬁc educational programs
designed to deter AAS abuse among adolescent boys.
Three distinct cohorts implemented Adolescents Training
and Learning to Avoid Steroids (ATLAS), which successfully inhibited AAS abuse among adolescent boys involved
in team sports.117,118 Results from the 1996 randomized,
prospective study,117 involving more than 1500 male youth
from 31 high schools, suggested the ATLAS intervention

Table 6. Possible Indicators of Anabolic-Androgenic Steroid Abuse
Behaviors

Dermatologic
Cardiovascular
Neuroendocrine
Musculoskeletal
a

Secretive actions, excessive dietary supplement use, mood swings, aggressiveness, excessive exercise,
periods of abnormal healthy patterns,a physique and/or diet obsession, high-risk behaviors, rapid
performance increases
Abnormal, excessive, or unexpected acne; jaundice, needle marks, abscesses
Changes toward hypertension, dyslipidemia
Male-pattern baldness, gynecomastia, testicular atrophy, female virilization (clitoral hypertrophy, hirsutism,
amenorrhea, breast reduction, voice changes)
Extreme musculature, rapid growth, extreme leanness, unexpected or unexplainable tendinopathies,
premature growth-plate closure

During an anabolic-androgenic steroid cycle (time period of abuse), individuals may simultaneously focus on healthy behaviors such as a
healthful diet, sufficient sleep, and regimented workouts.

decreased factors that encourage AAS misuse and lowered
the intent to abuse AAS while enhancing nutrition
behaviors. A follow-up 2000 ATLAS study118 reconﬁrmed
the earlier results with 31 high school football teams and
3207 student-athletes. Results suggested a signiﬁcant
reduction in the intent to abuse AAS as well as the actual
AAS abuse within the ATLAS intervention group. Other
abuse patterns also were reduced, including ingestion of
sport supplements, alcohol, and illicit drugs and illicit
drinking and driving behaviors.118
Athletes Targeting Healthy Exercise and Nutrition Alternatives (ATHENA) is a scripted, athletic team-centered,
peer-taught, and coach-facilitated program similar to ATLAS that focuses on adolescent female risk factors. More
than 925 students from 18 high schools in 2 states
participated. Compared with the control group, the ATHENA group used fewer athletic-enhancing substances, including AAS, amphetamines, supplements, and diet pills. In
addition, ATHENA participants improved their diets and
displayed fewer risky behaviors.116 Long-term follow-up (1
to 3 years after high school graduation) indicated persistently
lower rates of substance abuse.122 Both ATLAS and
ATHENA have undergone mediation analysis to assess the
reasons for the programs’ effectiveness.123,124 A systematic
review of educational programs commissioned by the World
Anti-Doping Agency showed that ATLAS and ATHENA
provided the only high-quality evidence available as to the
best way to educate adolescents about doping and are the
only programs that have been monitored regularly over an
extended follow-up period.121 Sex-speciﬁc, sport-centered,
and coach-facilitated educational programs that promote
performance-enhancing alternatives (eg, sport nutrition and
strength training) appear to be effective AAS abuse
deterrents for adolescent student-athletes.116–120 Presently,
other than adolescent educational AAS abuse-prevention
programs, no additional studies involving other populations
are found in the scientiﬁc literature.
AAS Abuse Identification and Intervention

Health care professionals and educators have a responsibility to assist individuals in making informed, positive
health decisions.22 The Board of Certiﬁcation details the
following areas of professional athletic training practice
related to AAS abuse: (1) injury/illness prevention and
wellness protection, (2) treatment and rehabilitation, and
(3) organizational and professional health and wellbeing.149 Recognizing AAS abuse or the intent to abuse
(one aspect of prevention); knowing when and how to
intervene (which guides referral options); and knowing how

to implement health care administration for those in need
all are responsibilities of athletic trainers.
AAS Abuse Identiﬁcation. Health care professionals
must understand the epidemiology of AAS abuse in strength
and power athletes, as well as other, sometimes less obvious
groups and individuals.3,8,9,34–49 A vigilant approach by
athletic trainers is critical due to their extended time spent
with these populations. The health care professional should
be aware of related conversations, as well as changes in
relationships,90,93 behaviors,54,67,68,82–85,128,145 and general
health,11,13,22,51,55,127 all of which can provide valuable
clues to AAS abuse. Although every situation varies, a
number of behavioral changes and other signs and symptoms
may indicate AAS abuse (Table 6).* If AAS abuse is
suspected, consider comparing the patient’s current medical
records with his or her baseline.
AAS Abuse Intervention. To date, no validated
management strategies are available for AAS abuse84; thus,
much of the following stems from anecdotal evidence or
experiences. Referral and counseling are paramount to
avoiding possible consequences of AAS abuse, such as
negative health effects and psychological dependence.149
However, not all health care professionals or educators
understand AAS pharmacology, the mentality of athletes and
AAS abusers, or common AAS abuse patterns.67,82,84 Few
AAS abusers seek treatment,84 and they are historically
skeptical of the medical-scientiﬁc establishment.5 As such,
health care professionals should develop a referral network
with other well-qualiﬁed colleagues, possibly including
specialists such as endocrinologists and psychiatrists.
Considering the various AAS abuse (or intent to abuse)
stages may assist health care professionals in offering
speciﬁc support, as described in the following examples.







Keep athletes’ self-esteem high with alternatives to AAS,
such as evidence-based nutrition and weight-training
principles, along with collaboration from conditioning
experts and sport nutritionists, among others.
Build trust with patients, clients, athletes, and coaches
through consistent, year-round, evidence-based educational
meetings and in-service sessions.
Avoid unfounded scare tactics and hype concerning the
negative consequences of AAS.
Be alert for excessive discussion about and focus on
supplements and nutrition practices or self-education about
AAS (eg, types, stacks, and cycles).

*References 11, 14, 22, 51, 54, 67, 68, 82–85, 90, 93, 127, 128,
133, 141, 145.
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Do not threaten suspected AAS abusers but instead
cautiously state your suspicions (eg, ‘‘I have noticed a
change in your behavior, supplement use, or interest in
AAS. . .’’) and offer evidence-based information and assistance. Be an accessible agent of positive behavioral
changes.
Acknowledge the minimal, short-term (physical) consequences of AAS abuse but stress education from health,
moral and ethical, and legal perspectives.
Comment on the negative aspects of AAS abuse, such as
increased acne, stunted growth, or jaundice (ie, the issues
younger adolescents and adults will likely be concerned
about). Be sure not to compliment their physical appearance
(eg, muscularity) or strength gains because this may
reinforce or encourage AAS abuse.
Discuss personal sacriﬁces that accompany AAS abuse,
such as money, time, social experiences, risk of disease and
injury, and counterfeit or tainted products, among others.
Remain attentive because AAS abusers typically are
secretive and good at not getting caught. A passed drug
screen does not prove AAS nonuse.

Consider using available tools, such as validated bodyimage screening instruments: for example, the male version
of the eating disorder inventory93 or the muscle dysmorphia
version145 of the Body Dysmorphic Disorder Modiﬁcation
of the Yale Brown Obsessive-Compulsive Scale. Objective
measures, such as the fat-free mass index, use basic
anthropometric data to determine the upper physiologic
limits of muscularity. Involve colleagues and other
professionals as part of a holistic approach. For instance,
integrate evidence-based strength and nutrition principles
into all activities and programs. Cooperatively implementing these techniques and principles may allow us to better
fulﬁll our comprehensive responsibility to athletes and the
physically active. That is, health care professionals should
constantly seek high-quality new resources and readily call
on available professionals, while coordinating the process
as with any other health care issue. Referral to an AASknowledgeable specialist for counseling and possible
pharmacologic intervention may be beneﬁcial.84
Health care professionals, including athletic trainers and
others, manage many illnesses and injuries in their clinical
practices.149 Each condition has unique characteristics and
clinical features, just as each AAS abuser is different.
Health care professionals may have a close relationship
with those in their care. Such relationships provide
excellent, critical opportunities to prevent AAS abuse
through an active approach that includes being alert to
abuse patterns, forthright in terms of approaching the issue,
and effective in offering counseling and referral services.
Health care professionals and educators serve as advocates
and resources for all those with health-related issues,
including AAS abuse.
CONCLUSIONS

Anabolic-androgenic steroids are powerful Schedule III
pharmaceuticals related to human androgens, primarily
testosterone. They act as both anabolic and androgenic
agents. Although these drugs have therapeutic roles, athletes
and nonathletes often abuse AAS to improve their physical
performance, physique, and body image. Abusers of AAS
most frequently use a cyclic, high-dose, multidrug regimen,
584
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the consequences of which are poorly understood. Rarely do
they obtain their information or their drugs from valid and
reliable sources. Anabolic-androgenic steroids carry a doserelated potential for increased lean body mass, and these
agents generally improve strength- and power-related
performances. Conversely, when abused, AAS may lead to
negative health effects on the central nervous, cardiovascular,
hepatic, reproductive, musculoskeletal, immune, integumentary, and nephritic systems and possibly others. Investigations
into useful techniques for preventing AAS abuse are limited.
Testing for AAS, by itself or in combination with other
interventions, is not well studied, and its deterrent efﬁcacy
remains uncertain. Well-designed and properly implemented
education appears to be useful for adolescent athletes, but
other populations remain understudied. Health care professionals and educators must manage the AAS abuser and
potential abuser based on the best available evidence,
including studies detailing prevention and intervention
strategies. Athletic trainers are health care professionals
who are often in a unique position to assess and assist AAS
abusers and those who may become AAS abusers.
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DISCLAIMER
The NATA and NATA Foundation publish their position
statements as a service to promote the awareness of certain issues
to its members. The information contained in the position
statement is neither exhaustive nor exclusive to all circumstances
or individuals. Variables such as institutional human resource
guidelines, state or federal statutes, rules, or regulations, as well
as regional environmental conditions, may impact the relevance
and implementation of these recommendations. The NATA and
NATA Foundation advise members and others to carefully and
independently consider each of the recommendations (including
the applicability of same to any particular circumstance or
individual). The position statement should not be relied upon as
an independent basis for care but rather as a resource available to
NATA members or others. Moreover, no opinion is expressed
herein regarding the quality of care that adheres to or differs from
the NATA and NATA Foundation position statements. The
NATA and NATA Foundation reserve the right to rescind or
modify position statements at any time.
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